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INTRODUCTION
Benzodiazepines are among the most commonly prescribed 
sedative-hypnotics and are highly prevalent (>10%) in elderly 
patients.1,2 However, many observational studies raised safety 
concerns over benzodiazepine use and the potential risk of 
dementia.3-5 Though the mechanism of the influence of ben-
zodiazepine on the development of dementia is uncertain, there 
are hypotheses that, based on the neural compensation and 
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cognitive reserve concepts, benzodiazepine users may utilize 
undamaged alternative neural networks to reduce cognitive 
disorders.6 However, by reducing the brain activation level, 
benzodiazepines could impair this ability and increase the po-
tential risk of dementia. Susceptibility to benzodiazepine-in-
duced dementia may differ across sex,7 age groups,8 and the 
use of multiple medications.9 Moreover, heterogeneity has 
been observed in individual safety profiles of benzodiazepine 
components.10
A meta-analysis, integrating four cohort studies and six 
case-control studies, reported that benzodiazepine users had 
a 78% higher potential risk of dementia compared to non-
users.11 A subsequent signal detection study using the US Food 
and Drug Administration Adverse Event Reporting System 
Database and the Canada Vigilance Adverse Reaction Online 
Database reported a 1.63-fold and 1.88-fold increased associ-
ation between benzodiazepine and dementia, respectively.10 
However, a prospective study found no significant differenc-
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es in the cognitive performance between benzodiazepine us-
ers and non-users.12
The safety of benzodiazepines has remained uncertain due 
to the inconsistent results of previous studies and the un-
known mechanisms by which benzodiazepine may influence 
dementia. The case/non-case method, derived from the case-
control study design used in epidemiology studies, is a phar-
macovigilance method validated for signal detection.13 Al-
though a previous case/non-case study reported an association 
between benzodiazepine use and memory disorders,14 selec-
tion bias may have undermined its results. All reports, except 
memory disorder cases, were selected as non-cases without 
balancing important demographic features. Our objective was 
to generate a reliable signal of the association between benzo-
diazepine use and the potential risk of cognitive impairment 
or dementia. We aimed to identify susceptible subgroups us-
ing a case/non-case method while controlling for the con-
founding of age and sex.
METHODS 
Data source
Reported cases related to cognitive impairment or demen-
tia were mined using Korea Institute of Drug Safety & Risk 
Management-Korea adverse event reporting system database 
(KIDS-KD).15 KIDS-KD consists of 9 tables: basic informa-
tion, drug information, ADR information, critical case infor-
mation, reporter information, causality assessment informa-
tion, disease history of ADR information, group information, 
and completeness information. Of 1,089,163 reports accumu-
lated in KIDS-KD between December 1988 and June 2016, 
212,127 reports related to benzodiazepine and other medica-
tions (opioid analgesics and antidepressants) were identified 
after excluding cases without age or sex and those younger 
than 40 years of age (Figure 1). This study was approved by 
the institutional review board of Sungkyunkwan University 
(No. 2017-08-008-001), which waived the informed consent, 
as only deidentified data were used in this study.
Case/non-case approach 
The case/non-case approach measures the disproportional-
ity of combinations between a drug and a particular ADR in 
a pharmacovigilance database.15-18 This approach was chosen 
to assess the disproportionality of reports for cognitive im-
pairment or dementia associated with benzodiazepines com-
pared to opioid analgesics or antidepressants. Reporting odds 
ratio (ROR) was calculated as the odds of the exposure to ben-
zodiazepines in comparison with that to other drugs (opioid 
analgesics, and antidepressants) in cases divided by the odds 
of the exposure to benzodiazepines in non-cases (Figure 2). 
To minimize data duplication, we eliminated reports whose 
report number, generic name, preferred terms (PTs) and in-
cluded terms (ITs) according to World Health Organization 
Adverse Reactions Terminology (WHO-ART) that were du-
plicated. Each case, defined as a report of cognitive impair-
ment or dementia, was matched to 10 non-cases by age and 
sex to minimize confounding from these variables. Cognitive 
impairment or dementia cases were defined using PTs and 
ITs of the four-level hierarchical system structure of WHO-
ART (adverse reaction record number: “0100,” “0199,” “1453,” 
and “1877”; Supplementary Table 1 in the online-only Data 
Supplement). Benzodiazepines were classified as short-, in-
termediate-, and long-acting according to half-lives; short-act-
ing <12 hours; intermediate-acting 12–23 hours; long-acting 
≥24.19,20 
Causality assessment 
In South Korea, the causality of each adverse event (AE) re-
port from healthcare professionals is evaluated using the mod-
ified algorithm based on the Naranjo algorithm developed by 
WHO-UMC.21 Using this algorithm, healthcare professionals 
including doctors, pharmacists, nurses, and pharmaceutical 
companies assess causality between drugs and AEs. The evi-
dence level is categorized into six groups: certain, probable/
likely, possible, unlikely, conditional/unclassified, and unas-
sessable. The items of the causality assessment algorithm in-
clude the time order between treatment and AEs, outcomes 
when the drugs were discontinued or re-administered, history 
of a similar reaction to the same or similar drugs in any previ-
ous exposure, concomitant drug use, presence of alternative 
causes of the reaction, and the presence of already known in-
formation on the AEs, based on the product labels or previ-
ous case reports. 
Potential confounders
Potential covariates for the association between benzodi-
azepine use and cognitive impairment or dementia were cat-
egorized as age group, sex, year of reporting, polypharmacy, 
and comorbidities. Polypharmacy was defined as a concomi-
tant prescription of ≥5 drugs.22 Comorbidities were coded us-
ing the 6th and 7th Korean Standard Classification of Diseas-
es (KCD) and included the following: renal failure, high blood 
pressure, paranoid schizophrenia, urinary incontinence, con-
stipation, other cholelithiasis, lower back pain, history of ma-
jor surgery, atrial fibrillation and flutter, bronchopneumonia, 
normal-pressure hydrocephalus, rheumatoid arthritis, hyper-
plasia of the prostate, malignant neoplasm of the bronchus or 
lung, cough, history of malignant neoplasm of digestive or-
gans, complex partial seizures developing into secondarily 
generalized seizures, migraines, atypical schizophrenia, other 
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cerebrovascular diseases, other and unspecified abdominal 
pain, dysuria, restlessness and agitation, hepatoma, multi-
ple myeloma, unspecified hypertension, spinal stenosis, and 
headaches. 
Additionally, reporting groups were assessed to judge the 
reliability of the reports. Reporting groups by profession were 
comprised of doctors, pharmacists, nurses, and consumers, 
based on information provided about the occupation of the 
person who made the report of the AEs. Reporting groups by 
affiliation consisted of hospitals/clinics, pharmacies, manu-
facturers, and consumers. 
Statistical analysis
Cases of benzodiazepine use, and comparator drug use were 
compared to determine whether benzodiazepine increases 
the signal of cognitive impairment or dementia. Logistic re-
gression analysis was conducted to estimate RORs and 95% 
confidence intervals (CIs). The models were adjusted for age, 
sex, year of reporting, polypharmacy, and comorbidities. 
Subgroup analysis was performed according to age group, 
sex, and polypharmacy. Sensitivity analyses were conducted 
Korea Institute of Drug Safety & Risk Management-Korea adverse event
reporting system database (KIDS-KD) drug-adverse event pairs for
benzodiazepines, opioids, antidepressants from 2007 to 2016
(N=1,086,584)
Korea Institute of Drug Safety & Risk Management-Korea adverse event
reporting system database (KIDS-KD) drug-adverse event pairs for
benzodiazepines, opioids, antidepressants from 2007 to 2016
(N=776,331)
Excluded (N=310,253)
Cases without age and sex
Cases younger than 40 years






Cognitive impairment or dementia cases
after matching on age and sex
(N=887)
Non-dementia cases after matching 












Figure 1. Flow-chart showing the selection of cases and non-cases for the signal evaluation study between the use of benzodiazepine and 
the risk of cognitive impairment or dementia Korea Institute of Drug Safety & Risk Management-Korea adverse event reporting system da-
tabase (KIDS-KD), 2007–2016.
Exposure Cognitive impairment or dementia cases
Non-dementia 
cases
Benzodiazepines A (N=56) B (N=289)
Others* 
*Opioid analgesics and 
  antidepressants
C (N=831) D (N=8,581)
Figure 2. RORs and 95% confidence intervals for cognitive impair-
ment or dementia and the use of benzodiazepines. ROR: reporting 
odds ratios.
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Table 1. Characteristics of the cases (cognitive impairment or dementia) and non-cases (non-dementia) matched by factors from KIDS-KD, 
2007–2016
Characteristics











Age group <0.001 1.00
40–44 54 (6.1) 60,596 (7.8) 54 (6.1) 540 (6.1) 
45–49 48 (5.4) 83,930 (10.8) 48 (5.4) 480 (5.4) 
50–54 26 (2.9) 120,610 (15.6) 26 (2.9) 260 (2.9) 
55–59 133 (15.0) 104,767 (13.5) 133 (15.0) 1,330 (15.0) 
60–64 171 (19.3) 96,275 (12.4) 171 (19.3) 1,710 (19.3) 
65–69 103 (11.6) 105,472 (13.6) 103 (11.6) 1,030 (11.6) 
70–74 87 (9.8) 98,039 (12.6) 87 (9.8) 870 (8.8) 
75–79 174 (19.6) 63,566 (8.2) 174 (19.6) 1,740 (19.6) 
80–84 28 (3.2) 31,716 (4.1) 28 (3.2) 280 (3.2) 
≥85 63 (7.1) 10,473 (1.4) 63 (7.1) 630 (7.1) 
Sex <0.078 1.00
Male 417 (47.0) 341,503 (44.0) 417 (47.0) 4,170 (47.0) 
Female 470 (53.0) 433,941 (56.0) 470 (53.0) 4,700 (53.0) 
Reporting group by profession <0.001 <0.001
Doctor 465 (52.4) 389,733 (50.3) 465 (52.4) 4,814 (54.3)
Pharmacist 81 (9.1) 57,138 (7.4) 81 (9.1) 646 (7.3)
Nurse 78 (8.8) 155,761 (20.1) 78 (8.8) 1,781 (20.1)
Consumer 12 (1.4) 5,211 (0.7) 12 (1.4) 63 (0.7)
Other healthcare professional 49 (5.5) 45,446 (5.9) 49 (5.5) 555 (6.3)
Reporting group by affiliation <0.001 <0.001
Hospitals/clinics 254 (28.6) 313,700 (40.5) 254 (28.6) 3,628 (40.9)
Pharmacies 10 (1.1) 13,389 (1.7) 10 (1.1) 134 (1.5)
Manufacturers 621 (70.0) 447,112 (57.7) 621 (70.0) 5,096 (57.5)
Consumers 2 (0.2) 850 (0.1) 2 (0.2) 7 (0.1)
Others 0 (0.0) 393 (0.1) 0 (0.0) 5 (0.1)
Polypharmacy (≥5) <0.078 <0.190
Yes 665 (75.0) 560,564 (72.3) 665 (75.0) 6465 (72.9) 
No 222 (25.0) 214,880 (27.7) 222 (25.0) 2405 (27.1) 
Comorbidities
Renal failure 69 (7.8) 1,690 (0.2) <0.001 69 (7.8) 23 (0.3) <0.001
Hypertension 53 (6.0) 8,028 (1.0) <0.001 53 (6.0) 90 (1.0) <0.001
Paranoid Schizophrenia 38 (4.3) 528 (0.1) <0.001 38 (4.3) 6 (0.1) <0.001
Urinary incontinence 35 (3.9) 561 (0.1) <0.001 35 (3.9) 7 (0.1) <0.001
Constipation 29 (3.3) 2,044 (0.3) <0.001 29 (3.3) 22 (0.2) <0.001
Other cholelithiasis 29 (3.3) 1,339 (0.2) <0.001 29 (3.3) 33 (0.4) <0.001
Low back pain 21 (2.4) 2,022 (0.3) <0.001 21 (2.4) 221 (2.5) <0.821
History of major surgery 21 (2.4) 10,572 (1.4) <0.010 21 (2.4) 306 (3.4) <0.088
AFF 14 (1.6) 109 (0.0) <0.001 14 (1.6) 1 (0.0) <0.001
Bronchopneumonia 14 (1.6) 57 (0.0) <0.001 14 (1.6) 3 (0.0) <0.001
NPH 13 (1.5) 35 (0.0) <0.001 13 (1.5) 1 (0.0) <0.001
RA 12 (1.4) 1,059 (0.1) <0.001 12 (1.4) 17 (0.2) <0.001
Hyperplasia of prostate 12 (1.4) 7,214 (0.9) <0.190 12 (1.4) 74 (0.8) <0.115
Lung cancer 11 (1.2) 4,891 (0.6) <0.022 11 (1.2) 54 (0.6) <0.028
Cough 10 (1.1) 1,059 (0.1) <0.001 10 (1.1) 11 (0.1) <0.001
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to assess bias in the causality of reports. Reports with causali-
ty assessments of “certain,” “probable,” and “possible” were an-
alyzed and the total number of cases was readjusted to 249,640, 
with 243 cognitive impairment or dementia cases and 249,397 
non-cases. After 1:10 matching, 243 cases, and 2,430 non-cas-
es were included. All statistical procedures were performed 
using the SAS 9.4 software (SAS Institute Inc., Cary, NC, USA). 
A two-tailed value of p<0.05 indicated statistical significance. 
RESULTS
From January 2007 to December 2016, there were 1,086,584 
AE-pairs pairs involving benzodiazepines that were identi-
fied. A total of 776,331 AE-pairs were included after exclud-
ing cases without age or sex (n=162,677) and those younger 
than 40 years of age (n=147,576). There were 887 cognitive im-
pairment or dementia AE-pairs defined as cases, and 775,444 
other AE-pairs were defined as non-cases. After 1:10 match-
ing according to age and sex, 887 cases and 8,870 non-cases 
were included. 
Table 1 shows the characteristics of cases and non-cases; 
75.9% and 87.9% of cognitive impairment or dementia cases 
and matched non-cases, respectively, were reported by health-
care professionals. Among the cases, disproportionality was 
found after any use of benzodiazepine as compared with non-
use. There was a difference in the magnitude of association 
before matching (adjusted ROR, aROR=2.04; 95% CI=1.55–
2.68) and after matching (aROR=2.23; 95% CI=1.61–3.09). 
Sensitivity analysis was implemented to limit AEs to those 
with certain, probable, or possible causality assessments; this 
restriction increased the disproportionality of benzodiazepine 
use (aROR=2.69; 95% CI=1.66–4.38) compared to that ob-
served across all AEs (Table 2). Individual benzodiazepine 
drugs had heterogeneous levels of safety profiles for cognitive 
impairment or dementia (Table 3). 
In the subgroup analysis (Table 4), there was no significant 
Table 1. Characteristics of the cases (cognitive impairment or dementia) and non-cases (non-dementia) matched by factors from KIDS-KD, 
2007–2016 (continued)
Characteristics











Year of reporting <0.002 <0.093
2007 28 (3.2) 50,401 (6.5) 28 (3.2) 206 (2.3) 
2008 16 (1.8) 8,821 (1.1) 16 (1.8) 111 (1.3) 
2009 35 (3.9) 12,410 (1.6) 35 (3.9) 150 (1.7) 
2010 107 (12.1) 35,558 (4.6) 107 (12.1) 378 (4.3) 
2011 35 (3.9) 37,978 (4.9) 35 (3.9) 452 (5.1) 
2012 17 (1.9) 53,666 (6.9) 17 (1.9) 622 (7.0) 
2013 129 (14.5) 180,911 (23.3) 129 (14.5) 1,891 (21.3) 
2014 23 (2.6) 46,587 (6.0) 23 (2.6) 537 (6.1) 
2015 155 (17.5) 171,127 (22.1) 155 (17.5) 2,239 (25.2) 
2016 342 (38.6) 177,985 (23.0) 342 (38.6) 2,284 (25.7) 
KIDS-KD: Korea Institute of Drug Safety & Risk Management-Korea adverse event reporting system database, AFF: atrial fibrillation and flutter, 
NPH: normal pressure hydrocephalus, RA: rheumatoid arthritis
Table 2. Disproportionality analysis of cognitive impairment or dementia associated with the use of benzodiazepines in all adverse events 
and applied to reports with certain, probable, and possible causality assessments from KIDS-KD, 2007–2016



























Including all causality assessments
Benzodiazepine 1.98 1.51 2.59 2.04 1.55 2.68 2.00 1.49 2.69 2.23 1.61 3.09
Restricted to adverse events with causality recorded as certain, probable, and/or possible
Benzodiazepine 2.85 1.87 4.35 2.70 1.76 4.12 2.58 1.62 4.12 2.69 1.66 4.38
*adjusted according to age group, sex, year of reporting, polypharmacy, and comorbidity. KIDS-KD: Korea Institute of Drug Safety & Risk Man-
agement-Korea adverse event reporting system database, ROR: reporting odds ratio, 95% CI: 95% confidence interval
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difference in RORs among different age groups. Higher ROR 
estimates were observed in female (aROR=2.33, 95% CI= 
1.48–3.67) than in male (aROR=1.89, 95% CI=1.11–3.20), 
and in those with polypharmacy (aROR=2.20, 95% CI=1.35–
3.57) than in those without polypharmacy (aROR=2.06, 95% 
CI=1.30–3.27). However, the subgroup difference was not 
statistically significant in the interaction test.
DISCUSSION
This case/non-case study using 10 years of spontaneous na-
tionwide reports showed that benzodiazepine use was associ-
ated with a potential risk of cognitive impairment or demen-
tia. Among the subgroups, higher RORs were observed in 
female and those who had polypharmacy. The possible asso-
Table 3. Disproportionality analysis of cognitive impairment or dementia associated with the use of individual benzodiazepines from KIDS-
KD, 2007–2016*




























Etizolam 1.36 0.42 4.36 1.55 0.48 5.03 1.20 0.33 4.36 1.26 0.28 5.64
Midazolam 0.49 0.21 1.15 0.44 0.18 1.05 0.46 0.19 1.12 0.36 0.13 1.00
Tofisopam 1.59 0.22 11.54 1.53 0.20 11.44 0.73 0.09 6.07 0.76 0.08 7.33
Triazolam 0.77 0.19 3.15 0.73 0.17 3.03 0.86 0.19 3.93 0.77 0.15 4.04
Intermediate-acting benzodiazepines
Alprazolam 1.13 0.60 2.14 1.23 0.64 2.36 1.24 0.61 2.52 1.72 0.75 3.97
Bromazepam 3.31 0.46 24.05 3.16 0.42 23.91 2.61 0.23 29.28 1.56 0.12 20.17
Flunitrazepam 8.75 2.11 36.31 7.32 1.64 32.58 2.64 0.47 14.77 1.38 0.15 12.53
Lorazepam 1.53 0.88 2.67 1.64 0.93 2.90 1.92 1.03 3.57 1.67 0.81 3.43
Long-acting benzodiazepines
Clonazepam 0.81 0.32 2.03 0.71 0.28 1.79 0.61 0.23 1.62 0.72 0.24 2.16
Diazepam 0.79 0.32 1.98 0.80 0.32 2.02 0.88 0.33 2.38 1.05 0.32 3.43
*analysis based on logistic on analysis, reference group: other benzodiazepines. This table displays only benzodiazepines referenced in over 
100 reports, †adjusted according to age group, sex, year of reporting, and polypharmacy. KIDS-KD: Korea Institute of Drug Safety & Risk Man-
agement-Korea adverse event reporting system database, ROR: reporting odds ratio, 95% CI: 95% confidence interval
Table 4. Subgroup analysis associated with factors for cognitive impairment or dementia: age (resetting for higher causality on cognitive im-
pairment or dementia), sex, and polypharmacy from KIDS-KD, 2007–2016




























≤64 2.13 1.47 3.09 1.80 1.21 2.68 1.92 1.28 2.87 2.37 1.46 3.84
65–74 1.77 0.94 3.35 1.69 0.88 3.25 2.19 1.09 4.41 2.22 1.04 4.75
≥75 1.80 1.08 2.98 2.24 1.32 3.82 2.06 1.19 3.59 2.33 1.22 4.44
Sex†
Male 1.88 1.24 2.84 1.51 0.96 2.38 1.78 1.14 2.79 1.89 1.11 3.20
Female 2.07 1.44 2.96 2.15 1.48 3.11 2.20 1.49 3.26 2.33 1.48 3.67
Polypharmacy‡
Yes 1.67 1.17 2.40 1.57 1.08 2.29 1.95 1.32 2.89 2.20 1.35 3.57
No 2.69 1.77 4.08 2.47 1.62 3.75 2.20 1.40 3.46 2.06 1.30 3.27
*adjusted for sex, polypharmacy, and comorbidity, †adjusted for age group, polypharmacy, and comorbidity, ‡adjusted for age group, sex, and 
comorbidity. KIDS-KD: Korea Institute of Drug Safety & Risk Management-Korea adverse event reporting system database, ROR: reporting 
odds ratio, 95% CI: 95% confidence interval
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ciation was supported by the disproportionality analysis, in 
which the magnitude of ROR increased when the analysis was 
restricted to reports suspected to have associations in the cau-
sality assessment by healthcare professionals. Benzodiazepine 
use was associated with a 2.69-fold increased report of cogni-
tive impairment or dementia when assessed using reports with 
certain, probable, and/or possible in causality assessments. Het-
erogeneity was observed in the individual safety profile of 
benzodiazepine components. 
Despite being statistically insignificant, higher ROR esti-
mates for cognitive decline/dementia in females and those 
with polypharmacy suggest that these subgroups are more 
susceptible to benzodiazepine-associated dementia risk. Simi-
lar findings that support our results are in a previously report-
ed systematic review which showed a higher association be-
tween benzodiazepine use and dementia among females (Odds 
ratio=1.16, 95% CI=1.00–1.36) than in males (1.00, 0.96–1.04).11 
Patients with polypharmacy have a particularly increased risk 
of benzodiazepine-induced cognitive impairment because 
benzodiazepines may trigger drug–drug interactions when 
concomitantly used with other drugs metabolized by CYP3A.23 
There was no difference in ROR estimates among different 
age groups. This can be due to the depletion of susceptible ef-
fects in older patients,24 in which these patients already at a high 
risk of dementia from other events associated with dementia 
such as neurological and psychiatric disorders, leading to a 
non-differential ROR compared to younger groups. We ob-
served a heterogeneity in the risk of individual benzodiazepine 
drugs, in contrast to the findings from the US FAERS database 
where the ROR values increased with the duration of benzo-
diazepine action. This inconsistency may be due to the dis-
crepancies in baseline characteristics among the users of dif-
ferent benzodiazepine components in our database or the 
difference in clinical indications.
Although the mechanism of the influence of benzodiaze-
pine on dementia is unknown, the following hypotheses sup-
port our results. First, benzodiazepine has neuro-sedative ef-
fects and causes cognitive deficits, which may lead to a decrease 
in cognitive reserve when used chronically.25,26 Second, chronic 
use of benzodiazepines could exacerbate dementia by down-
regulating gamma-aminobutyric acid (GABA) receptors.27,28 
Finally, benzodiazepine use may increase the potential risk of 
cognitive impairment in early dementia because of the GA-
BA-secreting activity expressed in amyloid plaques.29
Our observations are in line with previous pharmacoepide-
miologic studies reporting increasing potential risks among 
benzodiazepine users.3-5,30,31 The results are also consistent 
with those of a signal detection study conducted in Japan on 
the association between benzodiazepine use and the potential 
risk of dementia.10 A previous case/non-case study showed a 
greater association than did our study, reporting a more than 
6-fold increased reports of memory disorder among benzodi-
azepine users.14 Contrary to this, some cohort studies observed 
no association between benzodiazepine use and dementia.32,33
Our results are subject to reverse causation owing to the 
limitations of the AE reporting system database, which lacks 
information on the presence of biologically plausible lag time 
between benzodiazepine initiation and the occurrence of de-
mentia to consider disease latency. Provided that dementia has 
a latent period of several years and insidious onset, it is pos-
sible that benzodiazepines were prescribed for prodromal 
symptoms of dementia. However, given that over 75% of cog-
nitive impairment or dementia reports were from healthcare 
professionals in our database and the magnitude of ROR in-
creased when the analysis was restricted to reports suspected 
to have association in the causality assessment, our signal in-
dicates a possible association between benzodiazepine and 
the risk of cognitive impairment or dementia.
Our study has several strengths. We used a nationwide spon-
taneous reporting database, which accumulated 1,086,564 AE 
reports over 10 years. Second, the case/non-case design has an 
advantage in the feasibility of using demographic and clinical 
variables in the analyses, which has been a limitation of tradi-
tional signal detection methods, such as proportional report-
ing ratios, RORs, and information components. Since increas-
ing age and female sex are known risk factors for dementia, 
cases and non-cases were matched on these factors to exclude 
potential confounding. Matching is the most effective tech-
nique to increase comparability between cases and non-cas-
es because it ensures equal distributions of matching vari-
ables. We also performed multivariate analyses to control 
other confounders. Given that benzodiazepines are one of the 
most commonly used psychotropic drugs in elderly patients, 
our findings have important public health implications for 
this population. 
However, our study should be interpreted with caution. 
First, the limitations of spontaneous reporting may limit causal 
interpretation of our findings, as such reports are subject to 
the subjective judgments of the reporter. Second, our results 
are subject to protopathic bias and may have been influence 
by uncontrolled confounders as the database lacks clinical or 
demographic information. Important epidemiologic factors 
associated with dementia, such as depression, low education 
level, and smoking were not controlled in the analyses.34 Our 
analyses also did not reflect the influence of alcohol consump-
tion, which reportedly increases the potential risk of cogni-
tive impairment 3.6-fold,1 or body mass index (BMI). Obese 
patients (BMI >30) had a 74% increased risk of dementia 
compared to those with average weight.35 Third, the imbal-
ances of baseline characteristics between cases and non-cases 
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may lead to the ROR overestimations for benzodiazepine use 
and dementia. For example, the higher prevalence of paranoid 
schizophrenia among cases in which benzodiazepine may be 
used for the treatment may lead to a higher benzodiazepine 
prevalence and consequent ROR overestimation.36 Although 
we adjusted the comorbidities in the outcome model, the im-
balance of confounders between cases and non-cases may 
have resulted in ROR overestimations. Cognitive decline and 
dementia can be clinically different conditions. The difference 
between these two conditions lies in whether the patient has 
impaired activities of daily living.37 Due to the inherent limi-
tations of a retrospective study, it remains unclear how the clin-
ical judgement differentiated cognitive decline from demen-
tia. Nonetheless, we used both cognitive decline and dementia 
to define a case since these two conditions share common symp-
toms. Further, cognitive impairment can be a prodromal stage 
of dementia.38
In conclusion, our case/non-case study detected an increased 
association for cognitive impairment or dementia in female 
and in those with polypharmacy associated with benzodiaz-
epine use from a 10-year, cumulated AE database. We found 
inconsistencies in dementia safety profiles across benzodiaz-
epine components, which warrant further investigations. South 
Korea has a rapidly aging population, which is a non-modifi-
able potential risk factor for dementia.39 In this regard, the high 
prevalence of benzodiazepine use and its potential association 
with dementia are an important public health concern. We 
recommend further pharmacoepidemiologic studies to con-
firm our findings.
Supplementary Materials
The online-only Data Supplement is available with this ar-
ticle at https://doi.org/10.30773/pi.2019.0275.
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Supplementary Table 1. Case definitions using World Health Organization adverse reactions terminology
Categories ARRN Preferred terms
Cognitive decline 0199 Thinking abnormal, bradyphrenia, cerebration impaired, mental concentration difficulty, intellect impaired, 
  mental torpor, judgment impaired, mental dullness, thinking irrational, thought block, bradypsychic 
  responses, mental state abnormal, mental state abnormal aggravated, dyslogia, perception disturbance, 
  tachyphrenia
1877 Cognitive disorders, cognitive function abnormal, cognitive deterioration, acalculia, amusia
Dementia 0100 Dementia, dementia acquired, mental deterioration, dementia aggravation, Pick’s disease, senile dementia, 
  Korsakoff’s psychosis
1453 Alzheimer’s disease
ARRN: Adverse Reaction Record Number
